Rejuvenate Biomed researches the biology of aging & evaluates the therapeutic potential of safe and synergistic combination drugs that target physical decline as a common underlying concept to promote healthy aging.

Rejuvenate Biomed

Biology of aging

Major progress has been made in the biology of aging, also known as geroscience. This has resulted in a better scientific understanding of the biological processes associated with age-related functional decline. Several mechanisms (hallmarks of aging1 & hallmarks of health2) have been elucidated and drugable targets have been identified. At Rejuvenate Biomed, we identify opportunities to impact the aging process and develop new synergistic drug combinations that can positively influence cell health (mitochondrial, autophagy, ...), cell-cell communication and the immune system response.

1 López-Otín et al., Hallmarks of aging, Cell (2023)
2 López-Otín and Kroemer, Hallmarks of Health, Cell (2021)

Next-generation combinations

Within our in silico selection platform, we make use of large datasets and apply network biology to identify and evaluate safe prescription drugs. We combine these building blocks into new synergistic drug combinations that can restore complex biological systems. Our selection criteria contain, amongst others, human safety and efficacy potential to interact with longevity pathways. Our portfolio currently contains over 10 promising building blocks which have been selected via our platform. Our lead drug candidate RJx-01 is currently in Clinical Phase 1b, after generating positive preclinical data that are supportive to prevent and/or treat sarcopenia as a first age-related disease. We will define our second drug candidate RJx-02 by the end of 2022.

Our lead RJx-01

Chronic sarcopenia is the progressive age-associated loss of muscle function and mass and starts to manifest around the age of 50y, with muscle strength being lost at ~3% per year and mass at ~0.5-1.2% per year. This contributes to negative health outcomes, including an increased risk for disability, falls and fractures. Bedrest and hospitalization for an acute illness or surgery causes the acute development of sarcopenia due to an increased inflammatory burden in combination with muscle disuse (acute sarcopenia). The prevalence of sarcopenia in post-acute inpatient rehabilitation is 50%. Acute sarcopenia may be (partially) recoverable but increases the risk of chronic sarcopenia. Therefore, targeted interventions to prevent or reverse the effects are crucial. Preclinically, additional age-related indications have been identified as opportunities for RJx-01 to make a difference to people.


Clinical Phase 2b strategy endorsed by Advisory Board

Rejuvenate Biomed organized a Clinical Advisory Board meeting to discuss the clinical development of lead candidate RJx-01 in sarcopenia. After a fruitful brainstorming session, the Advisory Board supported the Phase 2b trial design, which will be initiated in 2023.

Groundbreaking clinical trial started

Rejuvenate Biomed started clinical trial with RJx-01 for treating sarcopenia. This trial marks Rejuvenate’s maturation from preclinical to clinical stage and is accompanied by the growth of the team and a move to the new Health Campus in Diepenbeek.

Dr. Ajit Shetty appointed as Chair of the Board

Rejuvenate Biomed appoints Dr. Ajit Shetty as Chair of the Board of Directors. As a veteran of the life sciences industry, Dr. Shetty will strengthen the business strategy of this ambitious company through both mentorship and connections.

Acknowledgements and Investors